PCM
RIGL icon

Penserra Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Penserra Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-390
Closed -$14K – 1518
2021
Q3 		$14K Buy
390
+2
+0.5% +$79 ﹤0.01% 1302
2021
Q2 		$16K Buy
388
+1
+0.3% +$38 ﹤0.01% 1204
2021
Q1 		$13K Sell
387
-16
-4% -$634 ﹤0.01% 1008
2020
Q4 		$14K Buy
403
+259
+180% +$7.5K ﹤0.01% 891
2020
Q3 		$3K Buy
+144
New +$3.54K ﹤0.01% 889

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Penserra Capital Management's RIGL Position: Q4 2021 in Review

Penserra Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 390 shares — an estimated $14K sold.

Penserra Capital Management first reported a position in RIGL in Q3 2020 and held it in 5 quarters. The position peaked at $16K in Q2 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • Penserra Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 390 Rigel Pharmaceuticals shares in Q4 2021, an estimated $14K.
  • Penserra Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Rigel Pharmaceuticals position peaked at $16K in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.